8-KOther Events

JOHNSON & JOHNSON 8-K Report, Corporate Update (Apr 21, 2005)

Filed April 21, 2005For Securities:JNJ

Summary

This 8-K filing from Johnson & Johnson (JNJ) on April 21, 2005, reports on a significant strategic acquisition. The company, through its subsidiary Ortho-McNeil Pharmaceutical, Inc., has entered into a definitive agreement to acquire Peninsula Pharmaceuticals, Inc., a privately held biopharmaceutical company. This move signals JNJ's commitment to bolstering its pharmaceutical pipeline, specifically in the critical area of antibiotics targeting life-threatening infections. The acquisition centers on Peninsula's lead product candidate, doripenem, a novel carbapenem antibiotic currently undergoing Phase III clinical trials for serious conditions like nosocomial pneumonia. The U.S. Food and Drug Administration (FDA) has granted doripenem Fast Track designation, highlighting its potential to address unmet medical needs. This acquisition is a key indicator of JNJ's strategy to invest in innovative therapies with strong growth potential and significant medical impact.

Key Highlights

  • 1Johnson & Johnson, via its subsidiary Ortho-McNeil Pharmaceutical, Inc., will acquire Peninsula Pharmaceuticals, Inc.
  • 2Peninsula Pharmaceuticals is a biopharmaceutical company focused on antibiotics for life-threatening infections.
  • 3The acquisition includes doripenem, a broad-spectrum carbapenem antibiotic candidate.
  • 4Doripenem is currently in six Phase III clinical trials.
  • 5Doripenem has received Fast Track designation from the FDA for treating nosocomial pneumonia, including ventilator-associated pneumonia (VAP).
  • 6The transaction is a cash-for-stock deal valued at approximately $245 million.
  • 7Johnson & Johnson anticipates a one-time after-tax charge of approximately $0.08 per share due to expensing the majority of the purchase price as in-process research and development.

Frequently Asked Questions

The primary purpose is to strengthen Johnson & Johnson's pharmaceutical pipeline by acquiring Peninsula Pharmaceuticals, Inc., a company specializing in novel antibiotics to combat life-threatening infections. This strategic move aims to add a promising drug candidate, doripenem, to JNJ's portfolio.

Doripenem is a broad-spectrum carbapenem antibiotic that is undergoing late-stage clinical trials (Phase III). The Fast Track designation from the FDA suggests that the agency recognizes doripenem's potential to address serious unmet medical needs in treating nosocomial pneumonia, including ventilator-associated pneumonia, potentially accelerating its path to market.

The acquisition is valued at approximately $245 million. Johnson & Johnson expects to incur a one-time after-tax charge of roughly $0.08 per share. This charge is primarily because most of the purchase price will be expensed as in-process research and development, a common accounting treatment for acquisitions of development-stage assets.

The acquisition is expected to close in the second quarter of 2005.